Overview
- The Science Signaling paper published Tuesday, November 17, 2026, reports that moderate-to-heavy ethanol exposure cut the benefit of anti-PD-1 treatment by about half in mouse models of lung and bladder cancer and raised tumor recurrence.
- Alcohol changed tumor-associated T cells by lowering tumor-infiltrating and tissue-resident memory T cells, shifting CD4+ cells from a Th1 to a Th17 profile, increasing TIGIT-expressing T cells, and activating SREBP-driven lipid programs.
- In mice, blocking TIGIT with antibodies restored anti-PD-1 responses and inhibiting SREBP signaling with the compound betulin produced partial recovery, pointing to actionable biological targets.
- A retrospective analysis of patients with skin, lung, bladder, or head and neck cancer found that people who self-reported eight or more drinks per week had worse survival after starting checkpoint inhibitors, with the signal clearest in lung cancer; the human data are limited by self-reporting and study design.
- Authors and commentators call for routine recording of alcohol use in cancer databases and for prospective clinical studies to test whether TIGIT- or SREBP-directed strategies can restore immunotherapy benefit in people who drink regularly.